Central EU committee makes case for faster EU drug approval process

The EU Committee ENVI recommends that the EU Commission expands its collaboration with the EMA for the faster approval of medicines, concerning the EU's pharmaceutical strategy.
BY PETER THOMSEN eu correspondent for Watch medier, translated by daniel pedersen

With a world-spanning health crisis behind it, and with its ambition of strengthening the health preparedness on the horizon, providing a better framework for the drug approval process in the EU is needed. This is the recommendation from one of the European Parliament's central committees, ENVI, for the EU's future pharmaceutical strategy.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading